Since Reductil was withdrawn from sale in January, we know a lot of customers have been very eager for any news as to whether this medication might be once again approved and regain its marketing license.
The European Medicines Agency originally withdrew this medication due to concerns raised by the SCOUT trial, which related to how well the medication was tolerated by people with existing heart conditions.
As the trial involved a patient group specifically excluded as candidates for the medication according to clinical practice, there was widespread consternation about the decision and we have already written in previous blogs that we expect Abbott, who manufacture Reductil , to mount an appeal against the decision.
So far, we know that Abbott have until the end of this month to put forward their objections to the European Commission, who have the power to overturn the decision.
We expect to hear more news about any decision that is taken by the middle of next month, but we will of course keep you updated if there are any further developments.